Could a single injection reprogram immune cells to tame lupus and scleroderma?
NCT ID NCT07523282
First seen Jun 26, 2026 · Last updated Aug 13, 2026 · Updated 3 times
Summary
This early study tests a new drug called HN2302, which aims to create CAR-T cells inside the body to target and control autoimmune diseases like lupus and scleroderma. The trial will enroll 12 adults to check safety and see if the treatment works. It is a first step, so results will show whether the approach is safe enough to study further.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HN2302 (in vivo CAR-T therapy)
- What this could lead to
- If it works, this could point toward a new way to control autoimmune diseases like lupus and scleroderma without needing lifelong medication.
- What could go wrong
- This is a very early, small Phase 1 trial with only 12 people. It is designed mainly to check safety, not yet to prove it works. There may be side effects or it may not help at all.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of University of Science and Technology of China
Hefei, Anhui, 230036, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can skin biopsies unlock new treatments for scleroderma?
- Could a skin patch ease stomach pain in scleroderma?
- Could a painless microneedle pad ease Raynaud's in scleroderma?
- Can a new biologic tame lupus flares?
- Could a single injection tame lupus and Sjögren's?
- Can a single infusion tame tough lupus?